{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:50:10Z","timestamp":1790776210154,"version":"4.1.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012681","name":"Centre National de la Recherche Scientifique","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012681","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["PLP20170939065"],"award-info":[{"award-number":["PLP20170939065"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR\u201010\u2010INBS\u201004"],"award-info":[{"award-number":["ANR\u201010\u2010INBS\u201004"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"ATIP\u2010Avenir program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008164","name":"The French Muscular Dystrophy Association","doi-asserted-by":"publisher","award":["17654"],"award-info":[{"award-number":["17654"]}],"id":[{"id":"10.13039\/100008164","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014865","name":"Fondation Maladies Rares","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014865","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"published-print":{"date-parts":[[2023,7,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Giant axonal neuropathy (GAN) is a fatal neurodegenerative disorder for which there is currently no treatment. Affecting the nervous system, GAN starts in infancy with motor deficits that rapidly evolve toward total loss of ambulation. Using the\n                    <jats:italic>gan<\/jats:italic>\n                    zebrafish model that reproduces the loss of motility as seen in patients, we conducted the first pharmacological screening for the GAN pathology. Here, we established a multilevel pipeline to identify small molecules restoring both the physiological and the cellular deficits in GAN. We combined behavioral,\n                    <jats:italic>in silico<\/jats:italic>\n                    , and high\u2010content imaging analyses to refine our Hits to five drugs restoring locomotion, axonal outgrowth, and stabilizing neuromuscular junctions in the\n                    <jats:italic>gan<\/jats:italic>\n                    zebrafish. The postsynaptic nature of the drug's cellular targets provides direct evidence for the pivotal role the neuromuscular junction holds in the restoration of motility. Our results identify the first drug candidates that can now be integrated in a repositioning approach to fasten therapy for the GAN disease. Moreover, we anticipate both our methodological development and the identified hits to be of benefit to other neuromuscular diseases.\n                  <\/jats:p>","DOI":"10.15252\/emmm.202216267","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T07:11:00Z","timestamp":1683270660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A multilevel screening pipeline in zebrafish identifies therapeutic drugs for GAN"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7115-7342","authenticated-orcid":false,"given":"L\u00e9a","family":"Lescouz\u00e8res","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7715-7167","authenticated-orcid":false,"given":"C\u00e9dric","family":"Hassen\u2010Khodja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0885-7933","authenticated-orcid":false,"given":"Ana\u00efs","family":"Baudot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4977-3939","authenticated-orcid":false,"given":"Beno\u00eet","family":"Bordignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7216-3261","authenticated-orcid":false,"given":"Pascale","family":"Bomont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"key":"BFEMMM202216267_CR1","unstructured":"[DATABASE] DrugBank https:\/\/go.drugbank.com\/"},{"key":"BFEMMM202216267_CR2","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1172\/JCI129788","volume":"129","author":"Y Arribat","year":"2019","unstructured":"Arribat Y, Mysiak KS, Lescouz\u00e8res L, Boizot A, Ruiz M, Rossel M, Bomont P (2019) Sonic hedgehog repression underlies gigaxonin mutation\u2013induced motor deficits in giant axonal neuropathy. J Clin Invest 129: 5312\u20135326","journal-title":"J Clin Invest"},{"key":"BFEMMM202216267_CR3","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.exer.2011.04.002","volume":"93","author":"S Arthur","year":"2011","unstructured":"Arthur S, Cantor LB (2011) Update on the role of alpha\u2010agonists in glaucoma management. Exp Eye Res 93: 271\u2013283","journal-title":"Exp Eye Res"},{"key":"BFEMMM202216267_CR4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF00686905","volume":"20","author":"AK Asbury","year":"1972","unstructured":"Asbury AK, Gale MK, Cox SC, Baringer JR, Berg BO (1972) Giant axonal neuropathy\u2014a unique case with segmental neurofilamentous masses. Acta Neuropathol 20: 237\u2013247","journal-title":"Acta Neuropathol"},{"key":"BFEMMM202216267_CR5","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1080\/01480545.2018.1463242","volume":"42","author":"HE Aslan","year":"2019","unstructured":"Aslan HE, Demir Y, \u00d6zaslan MS, T\u00fcrkan F, Beydemir \u015e, K\u00fcfrevio\u011flu \u00d6I (2019) The behavior of some chalcones on acetylcholinesterase and carbonic anhydrase activity. Drug Chem Toxicol 42: 634\u2013640","journal-title":"Drug Chem Toxicol"},{"key":"BFEMMM202216267_CR6","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1542\/peds.49.6.894","volume":"49","author":"BO Berg","year":"1972","unstructured":"Berg BO, Rosenberg SH, Asbury AK (1972) Giant axonal neuropathy. Pediatrics 49: 894\u2013899","journal-title":"Pediatrics"},{"key":"BFEMMM202216267_CR7","doi-asserted-by":"crossref","DOI":"10.1002\/syn.22009","volume":"71","author":"NI Bertone","year":"2017","unstructured":"Bertone NI, Groisman AI, Mazzone GL, Cano R, Tabares L, Uchitel OD (2017) Carbonic anhydrase inhibitor acetazolamide shifts synaptic vesicle recycling to a fast mode at the mouse neuromuscular junction. Synapse 71: e22009","journal-title":"Synapse"},{"key":"BFEMMM202216267_CR8","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2147\/NDT.S2056","volume":"4","author":"JD Best","year":"2008","unstructured":"Best JD, Alderton WK (2008) Zebrafish: an in vivo model for the study of neurological diseases. Neuropsychiatr Dis Treat 4: 567\u2013576","journal-title":"Neuropsychiatr Dis Treat"},{"key":"BFEMMM202216267_CR9","doi-asserted-by":"crossref","DOI":"10.1186\/2051-5960-2-47","volume":"2","author":"A Boizot","year":"2014","unstructured":"Boizot A, Talmat\u2010Amar Y, Morrogh D, Kuntz NL, Halbert C, Chabrol B, Houlden H, Stojkovic T, Schulman BA, Rautenstrauss B et\u00a0al (2014) The instability of the BTB\u2010KELCH protein Gigaxonin causes Giant axonal neuropathy and constitutes a new penetrant and specific diagnostic test. Acta Neuropathol Commun 2: 47","journal-title":"Acta Neuropathol Commun"},{"key":"BFEMMM202216267_CR10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/bs.mie.2015.07.009","volume":"569","author":"P Bomont","year":"2016","unstructured":"Bomont P (2016) Degradation of the intermediate filament family by Gigaxonin. Methods Enzymol 569: 215\u2013231","journal-title":"Methods Enzymol"},{"key":"BFEMMM202216267_CR11","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1080\/15548627.2019.1628546","volume":"15","author":"Bomont","year":"2019","unstructured":"Bomont (2019) GAN (gigaxonin) E3 ligase and ATG16L1: master and commander of autophagosome production. Autophagy 15: 1650\u20131652","journal-title":"Autophagy"},{"key":"BFEMMM202216267_CR12","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/hmg\/ddg092","volume":"12","author":"P Bomont","year":"2003","unstructured":"Bomont P, Koenig M (2003) Intermediate filament aggregation in fibroblasts of giant axonal neuropathy patients is aggravated in non dividing cells and by microtubule destabilization. Hum Mol Genet 12: 813\u2013822","journal-title":"Hum Mol Genet"},{"key":"BFEMMM202216267_CR13","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/81701","volume":"26","author":"P Bomont","year":"2000","unstructured":"Bomont P, Cavalier L, Blondeau F, Hamida CB, Belal S, Tazir M, Demir E, Topaloglu H, Korinthenberg R, T\u00fcys\u00fcz B et\u00a0al (2000) The gene encoding gigaxonin, a new member of the cytoskeletal BTB\/kelch repeat family, is mutated in giant axonal neuropathy. Nat Genet 26: 370\u2013374","journal-title":"Nat Genet"},{"key":"BFEMMM202216267_CR14","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s13311-019-00765-w","volume":"16","author":"P Bose","year":"2019","unstructured":"Bose P, Tremblay E, Maios C, Narasimhan V, Armstrong GAB, Liao M, Parker JA, Robitaille R, Wen XY, Barden C et\u00a0al (2019) The novel small molecule TRVA242 stabilizes neuromuscular junction defects in multiple animal models of amyotrophic lateral sclerosis. Neurotherapeutics 16: 1149\u20131166","journal-title":"Neurotherapeutics"},{"key":"BFEMMM202216267_CR15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094611","volume":"22","author":"E Bukharaeva","year":"2021","unstructured":"Bukharaeva E, Khuzakhmetova V, Dmitrieva S, Tsentsevitsky A (2021) Adrenoceptors modulate cholinergic synaptic transmission at the neuromuscular junction. Int J Mol Sci 22: 4611","journal-title":"Int J Mol Sci"},{"key":"BFEMMM202216267_CR16","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/sj.ejhg.5200476","volume":"8","author":"L Cavalier","year":"2000","unstructured":"Cavalier L, BenHamida C, Amouri R, Belal S, Bomont P, Lagarde N, Gressin L, Callen D, Demir E, Topaloglu H et\u00a0al (2000) Giant axonal neuropathy locus refinement to a <\u2009590 kb critical interval. Eur J Hum Genet 8: 527\u2013534","journal-title":"Eur J Hum Genet"},{"key":"BFEMMM202216267_CR17","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/hmg\/ddp044","volume":"18","author":"DW Cleveland","year":"2009","unstructured":"Cleveland DW, Yamanaka K, Bomont P (2009) Gigaxonin controls vimentin organization through a tubulin chaperone\u2010independent pathway. Hum Mol Genet 18: 1384\u20131394","journal-title":"Hum Mol Genet"},{"key":"BFEMMM202216267_CR18","doi-asserted-by":"crossref","unstructured":"Collymore C, Rasmussen S, Tolwani RJ (2013) Gavaging adult zebrafish. J Vis Exp 50691","DOI":"10.3791\/50691-v"},{"key":"BFEMMM202216267_CR19","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1471-4159.2008.05601.x","volume":"107","author":"F Dequen","year":"2008","unstructured":"Dequen F, Bomont P, Gowing G, Cleveland DW, Julien J\u2010P (2008) Modest loss of peripheral axons, muscle atrophy and formation of brain inclusions in mice with targeted deletion of gigaxonin exon 1. J Neurochem 107: 253\u2013264","journal-title":"J Neurochem"},{"key":"BFEMMM202216267_CR20","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1080\/15548627.2017.1375633","volume":"13","author":"A Du","year":"2017","unstructured":"Du A, Huang S, Zhao X, Feng K, Zhang S, Huang J, Miao X, Baggi F, Ostrom RS, Zhang Y et\u00a0al (2017) Suppression of CHRN endocytosis by carbonic anhydrase CAR3 in the pathogenesis of myasthenia gravis. Autophagy 13: 1981\u20131994","journal-title":"Autophagy"},{"key":"BFEMMM202216267_CR21","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0022-3565(25)21294-0","volume":"279","author":"FJ Ehlert","year":"1996","unstructured":"Ehlert FJ, Griffin MT, Glidden PF (1996) The interaction of the enantiomers of aceclidine with subtypes of the muscarinic receptor. J Pharmacol Exp Ther 279: 1335\u20131344","journal-title":"J Pharmacol Exp Ther"},{"key":"BFEMMM202216267_CR22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41586-019-1064-z","volume":"568","author":"MA El\u2010Brolosy","year":"2019","unstructured":"El\u2010Brolosy MA, Kontarakis Z, Rossi A, Kuenne C, G\u00fcnther S, Fukuda N, Kikhi K, Boezio GLM, Takacs CM, Lai S\u2010L et\u00a0al (2019) Genetic compensation triggered by mutant mRNA degradation. Nature 568: 193\u2013197","journal-title":"Nature"},{"key":"BFEMMM202216267_CR23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13023-019-1025-5","volume":"14","author":"J Finsterer","year":"2019","unstructured":"Finsterer J (2019) Congenital myasthenic syndromes. Orphanet J Rare Dis 14: 57","journal-title":"Orphanet J Rare Dis"},{"key":"BFEMMM202216267_CR24","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1326-6-25","volume":"6","author":"T Ganay","year":"2011","unstructured":"Ganay T, Boizot A, Burrer R, Chauvin J, Bomont P (2011) Sensory\u2010motor deficits and neurofilament disorganization in gigaxonin\u2010null mice. Mol Neurodegener 6: 25","journal-title":"Mol Neurodegener"},{"key":"BFEMMM202216267_CR25","first-page":"733","volume":"20","author":"N Garcia","year":"2005","unstructured":"Garcia N, Santaf\u00e9 MM, Salon I, Lanuza MA, Tom\u00e0s J (2005) Expression of muscarinic acetylcholine receptors (M1\u2010, M2\u2010, M3\u2010 and M4\u2010type) in the neuromuscular junction of the newborn and adult rat. Histol Histopathol 20: 733\u2013743","journal-title":"Histol Histopathol"},{"key":"BFEMMM202216267_CR26","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1476-5381.2010.00725.x","volume":"160","author":"J Giacomotto","year":"2010","unstructured":"Giacomotto J, S\u00e9galat L (2010) High\u2010throughput screening and small animal models, where are we?: high\u2010throughput screening and small animal models. Br J Pharmacol 160: 204\u2013216","journal-title":"Br J Pharmacol"},{"key":"BFEMMM202216267_CR27","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1472-8206.2009.00805.x","volume":"24","author":"B Haenisch","year":"2010","unstructured":"Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, B\u00f6nisch H (2010) Alpha\u2010adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol 24: 729\u2013739","journal-title":"Fundam Clin Pharmacol"},{"key":"BFEMMM202216267_CR28","volume-title":"Nonparametric statistical methods","author":"M Hollander","year":"2014","unstructured":"Hollander M, Wolfe DA, Chicken E (2014) Nonparametric statistical methods, 3rd edn. Hoboken, NJ: John Wiley & Sons, Inc","edition":"3rd edn"},{"key":"BFEMMM202216267_CR29","first-page":"65","volume":"6","author":"S Holm","year":"1979","unstructured":"Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Stat 6: 65\u201370","journal-title":"Scand J Stat"},{"key":"BFEMMM202216267_CR30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/35049541","volume":"1","author":"TM Jessell","year":"2000","unstructured":"Jessell TM (2000) Neuronal specification in the spinal cord: inductive signals and transcriptional codes. Nat Rev Genet 1: 20\u201329","journal-title":"Nat Rev Genet"},{"key":"BFEMMM202216267_CR31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1136\/jnnp-2018-318834","volume":"90","author":"M Juneja","year":"2019","unstructured":"Juneja M, Burns J, Saporta MA, Timmerman V (2019) Challenges in modelling the Charcot\u2010Marie\u2010tooth neuropathies for therapy development. J Neurol Neurosurg Psychiatry 90: 58\u201367","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFEMMM202216267_CR32","doi-asserted-by":"crossref","first-page":"5331","DOI":"10.1073\/pnas.1102116108","volume":"108","author":"G Kawahara","year":"2011","unstructured":"Kawahara G, Karpf JA, Myers JA, Alexander MS, Guyon JR, Kunkel LM (2011) Drug screening in a zebrafish model of Duchenne muscular dystrophy. Proc Natl Acad Sci USA 108: 5331\u20135336","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFEMMM202216267_CR33","doi-asserted-by":"crossref","unstructured":"Kinkel MD, Eames SC, Philipson LH, Prince VE (2010) Intraperitoneal injection into adult zebrafish. J Vis Exp 2126","DOI":"10.3791\/2126"},{"key":"BFEMMM202216267_CR34","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nchembio.307","volume":"6","author":"D Kokel","year":"2010","unstructured":"Kokel D, Bryan J, Laggner C, White R, Cheung CYJ, Mateus R, Healey D, Kim S, Werdich AA, Haggarty SJ et\u00a0al (2010) Rapid behavior\u2010based identification of neuroactive small molecules in the zebrafish. Nat Chem Biol 6: 231\u2013237","journal-title":"Nat Chem Biol"},{"key":"BFEMMM202216267_CR35","volume-title":"GeneReviews\u00ae","author":"G Kuhlenb\u00e4umer","year":"2020","unstructured":"Kuhlenb\u00e4umer G, Timmerman V, Bomont P (2020) Giant axonal neuropathy. In GeneReviews\u00ae, Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, Amemiya A (eds). Seattle, WA: University of Washington"},{"key":"BFEMMM202216267_CR36","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nchembio.732","volume":"8","author":"C Laggner","year":"2012","unstructured":"Laggner C, Kokel D, Setola V, Tolia A, Lin H, Irwin JJ, Keiser MJ, Cheung CYJ, Minor DL, Roth BL et\u00a0al (2012) Chemical informatics and target identification in a zebrafish phenotypic screen. Nat Chem Biol 8: 144\u2013146","journal-title":"Nat Chem Biol"},{"key":"BFEMMM202216267_CR37","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/WCO.0000000000000735","volume":"32","author":"M Laur\u00e1","year":"2019","unstructured":"Laur\u00e1 M, Pipis M, Rossor AM, Reilly MM (2019) Charcot\u2010Marie\u2010tooth disease and related disorders: an evolving landscape. Curr Opin Neurol 32: 641\u2013650","journal-title":"Curr Opin Neurol"},{"key":"BFEMMM202216267_CR38","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1093\/hmg\/ddm193","volume":"16","author":"R Lemmens","year":"2007","unstructured":"Lemmens R, Van Hoecke A, Hersmus N, Geelen V, D'Hollander I, Thijs V, Van Den Bosch L, Carmeliet P, Robberecht W (2007) Overexpression of mutant superoxide dismutase 1 causes a motor axonopathy in the zebrafish. Hum Mol Genet 16: 2359\u20132365","journal-title":"Hum Mol Genet"},{"key":"BFEMMM202216267_CR39","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.01022","volume":"11","author":"L Lescouz\u00e8res","year":"2020","unstructured":"Lescouz\u00e8res L, Bomont P (2020) E3 ubiquitin ligases in neurological diseases: focus on Gigaxonin and autophagy. Front Physiol 11: 1022","journal-title":"Front Physiol"},{"key":"BFEMMM202216267_CR40","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.956582","volume":"15","author":"L Lescouz\u00e8res","year":"2022","unstructured":"Lescouz\u00e8res L, Bordignon B, Bomont P (2022) Development of a high\u2010throughput tailored imaging method in zebrafish to understand and treat neuromuscular diseases. Front Mol Neurosci 15: 956582","journal-title":"Front Mol Neurosci"},{"key":"BFEMMM202216267_CR41","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1146\/annurev-physiol-022516-034255","volume":"80","author":"L Li","year":"2018","unstructured":"Li L, Xiong W\u2010C, Mei L (2018) Neuromuscular junction formation, aging, and disorders. Annu Rev Physiol 80: 159\u2013188","journal-title":"Annu Rev Physiol"},{"key":"BFEMMM202216267_CR42","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41586-019-1057-y","volume":"568","author":"Z Ma","year":"2019","unstructured":"Ma Z, Zhu P, Shi H, Guo L, Zhang Q, Chen Y, Chen S, Zhang Z, Peng J, Chen J (2019) PTC\u2010bearing mRNA elicits a genetic compensation response via Upf3a and COMPASS components. Nature 568: 259\u2013263","journal-title":"Nature"},{"key":"BFEMMM202216267_CR43","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrd4627","volume":"14","author":"CA MacRae","year":"2015","unstructured":"MacRae CA, Peterson RT (2015) Zebrafish as tools for drug discovery. Nat Rev Drug Discov 14: 721\u2013731","journal-title":"Nat Rev Drug Discov"},{"key":"BFEMMM202216267_CR44","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2165\/11593300-000000000-00000","volume":"31","author":"L Maggi","year":"2011","unstructured":"Maggi L, Mantegazza R (2011) Treatment of myasthenia gravis: focus on pyridostigmine. Clin Drug Investig 31: 691\u2013701","journal-title":"Clin Drug Investig"},{"key":"BFEMMM202216267_CR45","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1172\/JCI66387","volume":"123","author":"S Mahammad","year":"2013","unstructured":"Mahammad S, Murthy SNP, Didonna A, Grin B, Israeli E, Perrot R, Bomont P, Julien J\u2010P, Kuczmarski E, Opal P et\u00a0al (2013) Giant axonal neuropathy\u2013associated gigaxonin mutations impair intermediate filament protein degradation. J Clin Invest 123: 1964\u20131975","journal-title":"J Clin Invest"},{"key":"BFEMMM202216267_CR46","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nbt1186","volume":"24","author":"N Malo","year":"2006","unstructured":"Malo N, Hanley JA, Cerquozzi S, Pelletier J, Nadon R (2006) Statistical practice\u00a0in high\u2010throughput screening data analysis. Nat Biotechnol 24: 167\u2013175","journal-title":"Nat Biotechnol"},{"key":"BFEMMM202216267_CR47","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1517\/13543776.2013.794788","volume":"23","author":"E Masini","year":"2013","unstructured":"Masini E, Carta F, Scozzafava A, Supuran CT (2013) Antiglaucoma carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat 23: 705\u2013716","journal-title":"Expert Opin Ther Pat"},{"key":"BFEMMM202216267_CR48","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.mcn.2011.12.007","volume":"49","author":"S Mazhar","year":"2012","unstructured":"Mazhar S, Herbst R (2012) The formation of complex acetylcholine receptor clusters requires MuSK kinase activity and structural information from the MuSK extracellular domain. Mol Cell Neurosci 49: 475\u2013486","journal-title":"Mol Cell Neurosci"},{"key":"BFEMMM202216267_CR49","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13024-016-0122-3","volume":"11","author":"A McGown","year":"2016","unstructured":"McGown A, Shaw DPJ, Ramesh T (2016) ZNStress: a high\u2010throughput drug screening protocol for identification of compounds modulating neuronal stress in the transgenic mutant sod1G93R zebrafish model of amyotrophic lateral sclerosis. Mol Neurodegener 11: 56","journal-title":"Mol Neurodegener"},{"key":"BFEMMM202216267_CR50","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pcl.2019.09.002","volume":"67","author":"C Michel","year":"2020","unstructured":"Michel C, Collins C (2020) Pediatric neuromuscular disorders. Pediatr Clin North Am 67: 45\u201357","journal-title":"Pediatr Clin North Am"},{"key":"BFEMMM202216267_CR52","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/B978-141602908-3.50018-2","volume-title":"Cerebrospinal Fluid in Clinical Practice","author":"BM Morrison","year":"2009","unstructured":"Morrison BM, Griffin JW (2009) Neuromuscular diseases. In Cerebrospinal Fluid in Clinical Practice, pp 121\u2013126. Baltimore: Elsevier"},{"key":"BFEMMM202216267_CR53","volume":"14","author":"A\u2010M Opri\u015foreanu","year":"2021","unstructured":"Opri\u015foreanu A\u2010M, Smith HL, Krix S, Chaytow H, Carragher NO, Gillingwater TH, Becker CG, Becker T (2021) Automated in vivo drug screen in zebrafish identifies synapse\u2010stabilising drugs with relevance to spinal muscular atrophy. Dis Model Mech 14: dmm047761","journal-title":"Dis Model Mech"},{"key":"BFEMMM202216267_CR54","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ydbio.2005.06.027","volume":"285","author":"JA Panzer","year":"2005","unstructured":"Panzer JA, Gibbs SM, Dosch R, Wagner D, Mullins MC, Granato M, Balice\u2010Gordon RJ (2005) Neuromuscular synaptogenesis in wild\u2010type and mutant zebrafish. Dev Biol 285: 340\u2013357","journal-title":"Dev Biol"},{"key":"BFEMMM202216267_CR55","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s12017-013-8228-z","volume":"15","author":"A Pappalardo","year":"2013","unstructured":"Pappalardo A, Pitto L, Fiorillo C, Alice Donati M, Bruno C, Santorelli FM (2013) Neuromuscular disorders in zebrafish: state of the art and future perspectives. Neuromolecular Med 15: 405\u2013419","journal-title":"Neuromolecular Med"},{"key":"BFEMMM202216267_CR56","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.97152","volume":"2","author":"SA Patten","year":"2017","unstructured":"Patten SA, Aggad D, Martinez J, Tremblay E, Petrillo J, Armstrong GA, La Fontaine A, Maios C, Liao M, Ciura S et\u00a0al (2017) Neuroleptics as therapeutic compounds stabilizing neuromuscular transmission in amyotrophic lateral sclerosis. JCI Insight 2: e97152","journal-title":"JCI Insight"},{"key":"BFEMMM202216267_CR57","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41573-021-00210-8","volume":"20","author":"EE Patton","year":"2021","unstructured":"Patton EE, Zon LI, Langenau DM (2021) Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials. Nat Rev Drug Discov 20: 611\u2013628","journal-title":"Nat Rev Drug Discov"},{"key":"BFEMMM202216267_CR58","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.581098","volume":"11","author":"DM Perez","year":"2020","unstructured":"Perez DM (2020) \u03b11\u2010adrenergic receptors in neurotransmission, synaptic plasticity, and cognition. Front Pharmacol 11: 581098","journal-title":"Front Pharmacol"},{"key":"BFEMMM202216267_CR59","doi-asserted-by":"crossref","first-page":"12965","DOI":"10.1073\/pnas.97.24.12965","volume":"97","author":"RT Peterson","year":"2000","unstructured":"Peterson RT, Link BA, Dowling JE, Schreiber SL (2000) Small molecule developmental screens reveal the logic and timing of vertebrate development. Proc Natl Acad Sci USA 97: 12965\u201312969","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFEMMM202216267_CR60","doi-asserted-by":"crossref","unstructured":"Pugach EK, Li P, White R, Zon L (2009) Retro\u2010orbital injection in adult zebrafish. J Vis Exp 1645","DOI":"10.3791\/1645-v"},{"key":"BFEMMM202216267_CR61","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C et\u00a0al (2019) Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 18: 41\u201358","journal-title":"Nat Rev Drug Discov"},{"key":"BFEMMM202216267_CR62","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2019","unstructured":"R Core Team (2019) R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing"},{"key":"BFEMMM202216267_CR63","doi-asserted-by":"crossref","first-page":"R55","DOI":"10.1093\/hmg\/ddz131","volume":"28","author":"B Ravi","year":"2019","unstructured":"Ravi B, Antonellis A, Sumner CJ, Lieberman AP (2019) Genetic approaches to the treatment of inherited neuromuscular diseases. Hum Mol Genet 28: R55\u2013R64","journal-title":"Hum Mol Genet"},{"key":"BFEMMM202216267_CR64","first-page":"215","volume":"49","author":"L Re","year":"1999","unstructured":"Re L (1999) Modulation of acetylcholine release by presynaptic muscarinic autoreceptors. Acta Physiol Pharmacol Ther Latinoam 49: 215\u2013223","journal-title":"Acta Physiol Pharmacol Ther Latinoam"},{"key":"BFEMMM202216267_CR65","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cbpa.2014.10.025","volume":"24","author":"AJ Rennekamp","year":"2015","unstructured":"Rennekamp AJ, Peterson RT (2015) 15\u2009years of zebrafish chemical screening. Curr Opin Chem Biol 24: 58\u201370","journal-title":"Curr Opin Chem Biol"},{"key":"BFEMMM202216267_CR66","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1126\/science.1183090","volume":"327","author":"J Rihel","year":"2010","unstructured":"Rihel J, Prober DA, Arvanites A, Lam K, Zimmerman S, Jang S, Haggarty SJ, Kokel D, Rubin LL, Peterson RT et\u00a0al (2010) Zebrafish behavioral profiling links drugs to biological targets and rest\/wake regulation. Science 327: 348\u2013351","journal-title":"Science"},{"key":"BFEMMM202216267_CR67","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.nmd.2011.02.012","volume":"21","author":"SA Robb","year":"2011","unstructured":"Robb SA, Sewry CA, Dowling JJ, Feng L, Cullup T, Lillis S, Abbs S, Lees MM, Laporte J, Manzur AY et\u00a0al (2011) Impaired neuromuscular transmission and response to acetylcholinesterase inhibitors in centronuclear myopathies. Neuromuscul Disord 21: 379\u2013386","journal-title":"Neuromuscul Disord"},{"key":"BFEMMM202216267_CR69","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nchembio.1199","volume":"9","author":"M Schenone","year":"2013","unstructured":"Schenone M, Dan\u010d\u00edk V, Wagner BK, Clemons PA (2013) Target identification and mechanism of action in chemical biology and drug discovery. Nat Chem Biol 9: 232\u2013240","journal-title":"Nat Chem Biol"},{"key":"BFEMMM202216267_CR70","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41467-019-08331-w","volume":"10","author":"A Scrivo","year":"2019","unstructured":"Scrivo A, Codogno P, Bomont P (2019) Gigaxonin E3 ligase governs ATG16L1 turnover to control autophagosome production. Nat Commun 10: 780","journal-title":"Nat Commun"},{"key":"BFEMMM202216267_CR71","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120493","volume":"3","author":"PR Serafini","year":"2018","unstructured":"Serafini PR, Feyder MJ, Hightower RM, Garcia\u2010Perez D, Vieira NM, Lek A, Gibbs DE, Moukha\u2010Chafiq O, Augelli\u2010Szafran CE, Kawahara G et\u00a0al (2018) A limb\u2010girdle muscular dystrophy 2I model of muscular dystrophy identifies corrective drug compounds for dystroglycanopathies. JCI Insight 3: e120493","journal-title":"JCI Insight"},{"key":"BFEMMM202216267_CR72","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498\u20132504","journal-title":"Genome Res"},{"key":"BFEMMM202216267_CR73","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019932","volume":"8","author":"M Stam","year":"2018","unstructured":"Stam M, Wadman RI, Wijngaarde CA, Bartels B, Asselman F\u2010L, Otto LAM, Goedee HS, Habets LE, de Groot JF, Schoenmakers MAGC et\u00a0al (2018) Protocol for a phase II, monocentre, double\u2010blind, placebo\u2010controlled, cross\u2010over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2\u20104 (SPACE trial). BMJ Open 8: e019932","journal-title":"BMJ Open"},{"key":"BFEMMM202216267_CR87","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.devcel.2015.08.006","volume":"34","author":"J Sun","year":"2015","unstructured":"Sun J, Pan CQ, Chew TW, Liang F, Burmeister M, Low BC (2015) BNIP-H recruits the cholinergic machinery to neurite terminals to promote acetylcholine signaling and neuritogenesis. Dev Cell 34: 555\u2013568","journal-title":"Dev Cell"},{"key":"BFEMMM202216267_CR74","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrd2467","volume":"7","author":"CT Supuran","year":"2008","unstructured":"Supuran CT (2008) Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 7: 168\u2013181","journal-title":"Nat Rev Drug Discov"},{"key":"BFEMMM202216267_CR75","doi-asserted-by":"crossref","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta\u2010Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P et\u00a0al (2019) STRING v11: protein\u2013protein association networks with increased coverage, supporting functional discovery in genome\u2010wide experimental datasets. Nucleic Acids Res 47: D607\u2013D613","journal-title":"Nucleic Acids Res"},{"key":"BFEMMM202216267_CR76","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1023\/A:1019940932275","volume":"23","author":"G Te Kronnie","year":"2002","unstructured":"Te Kronnie G, Reggiani C (2002) Skeletal muscle fibre type specification during embryonic development. J Muscle Res Cell Motil 23: 65\u201369","journal-title":"J Muscle Res Cell Motil"},{"key":"BFEMMM202216267_CR77","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.neulet.2017.04.015","volume":"649","author":"AN Tsentsevitsky","year":"2017","unstructured":"Tsentsevitsky AN, Kovyazina IV, Nurullin LF, Nikolsky EE (2017) Muscarinic cholinoreceptors (M1\u2010, M2\u2010, M3\u2010 and M4\u2010type) modulate the acetylcholine secretion in the frog neuromuscular junction. Neurosci Lett 649: 62\u201369","journal-title":"Neurosci Lett"},{"key":"BFEMMM202216267_CR78","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/nm.2901","volume":"18","author":"A Van Hoecke","year":"2012","unstructured":"Van Hoecke A, Schoonaert L, Lemmens R, Timmers M, Staats KA, Laird AS, Peeters E, Philips T, Goris A, Dubois B et\u00a0al (2012) EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat Med 18: 1418\u20131422","journal-title":"Nat Med"},{"key":"BFEMMM202216267_CR79","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1093\/brain\/awz322","volume":"142","author":"AE Vanhaesebrouck","year":"2019","unstructured":"Vanhaesebrouck AE, Webster R, Maxwell S, Rodriguez Cruz PM, Cossins J, Wickens J, Liu W\u2010W, Cetin H, Cheung J, Ramjattan H et\u00a0al (2019) \u03b22\u2010adrenergic receptor agonists ameliorate the adverse effect of long\u2010term pyridostigmine on neuromuscular junction structure. Brain 142: 3713\u20133727","journal-title":"Brain"},{"key":"BFEMMM202216267_CR80","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.biopsych.2013.04.025","volume":"74","author":"B Voleti","year":"2013","unstructured":"Voleti B, Navarria A, Liu R\u2010J, Banasr M, Li N, Terwilliger R, Sanacora G, Eid T, Aghajanian G, Duman RS (2013) Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis,\u00a0and antidepressant behavioral responses. Biol Psychiatry 74: 742\u2013749","journal-title":"Biol Psychiatry"},{"key":"BFEMMM202216267_CR81","volume":"7","author":"SL Walker","year":"2012","unstructured":"Walker SL, Ariga J, Mathias JR, Coothankandaswamy V, Xie X, Distel M, K\u00f6ster RW, Parsons MJ, Bhalla KN, Saxena MT et\u00a0al (2012) Automated reporter quantification In vivo: high\u2010throughput screening method for reporter\u2010based assays in zebrafish. PLoS ONE 7: e29916","journal-title":"PLoS ONE"},{"key":"BFEMMM202216267_CR86","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1152\/jn.90517.2008","volume":"100","author":"M Wang","year":"2008","unstructured":"Wang M, Wen H, Brehm P (2008) Function of neuromuscular synapses in the zebrafish choline-acetyltransferase mutant bajan. J Neurophysiol 100: 1995\u20132004","journal-title":"J Neurophysiol"},{"key":"BFEMMM202216267_CR82","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z et\u00a0al (2018) DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 46: D1074\u2013D1082","journal-title":"Nucleic Acids Res"},{"key":"BFEMMM202216267_CR83","doi-asserted-by":"crossref","first-page":"14942","DOI":"10.1523\/JNEUROSCI.2276-09.2009","volume":"29","author":"MC Wright","year":"2009","unstructured":"Wright MC, Potluri S, Wang X, Dentcheva E, Gautam D, Tessler A, Wess J, Rich MM, Son Y\u2010J (2009) Distinct muscarinic acetylcholine receptor subtypes contribute to stability and growth, but not compensatory plasticity, of neuromuscular synapses. J Neurosci 29: 14942\u201314955","journal-title":"J Neurosci"},{"key":"BFEMMM202216267_CR84","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","volume":"4","author":"J\u2010H Zhang","year":"1999","unstructured":"Zhang J\u2010H, Chung TDY, Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4: 67\u201373","journal-title":"J Biomol Screen"},{"key":"BFEMMM202216267_CR85","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/368140a0","volume":"368","author":"JQ Zheng","year":"1994","unstructured":"Zheng JQ, Felder M, Connor JA, Poo M (1994) Turning of nerve growth cones induced by neurotransmitters. Nature 368: 140\u2013144","journal-title":"Nature"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.15252\/emmm.202216267.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.15252\/emmm.202216267\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.embopress.org\/doi\/pdf\/10.15252\/emmm.202216267","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.15252\/emmm.202216267.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:43:49Z","timestamp":1779086629000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.15252\/emmm.202216267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":85,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,10]]}},"alternative-id":["BFEMMM202216267"],"URL":"https:\/\/doi.org\/10.15252\/emmm.202216267","relation":{},"ISSN":["1757-4676","1757-4684"],"issn-type":[{"value":"1757-4676","type":"print"},{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]},"assertion":[{"value":"11 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"EMMM202216267"}}